Filterlex Medical, a Caesarea,, Israel-based cardiovascular medical device startup, closed a US $6M Series A1 funding.
The backers were not disclosed.
The company intends to use the funds to accelerate implementation of its CAPTIS® clinical program.
Led by Sigal Eli, Founder and CEO, Filterlex Medical is a cardiovascular medical device startup developing the CAPTIS®, a full-body embolic protection device. In 2016, the company joined Alon MedTech Ventures incubator, owned by Dr. Shimon Eckhouse, an entrepreneur and investor in the field of medical devices.
The CAPTIS is a next-generation, full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures. During catheter-based procedures, such as Transcatheter Aortic Valve Replacement (TAVR), embolic particles are often released into the blood flow and may cause neurological deficiencies, from cognitive impairment to debilitating stroke. As demonstrated in a first-in-human study, the device is deployed and retrieved. It is securely positioned in the aorta, protecting its surface, while facilitating a seamless TAVR procedure. The CAPTIS requires no additional arterial access and does not interfere with the procedure workflow.